Status:
UNKNOWN
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Lead Sponsor:
Isfahan University of Medical Sciences
Conditions:
Neuromuscular Diseases
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year. Complex nature and unknown pathogenesis of this disease are 2 major r...
Eligibility Criteria
Inclusion
- Patients diagnosed as definite or probable ALS according to El Escorial Criteria.
- ALS patients who are graded as mild or moderate according to ALS Health State Scale.
- Forced vital capacity of at least 80%
- Desire of the patient to participate in this study and Signing Written Informed Consent.
Exclusion
- Incidence of drug's side effects that requires discontinuation of the drug (Edaravone's side effects: Acute kidney injury, Acute allergic reactions, DIC, Thrombocytopenia, Leukopenia).
- Desire of the patient to discontinue participating in this study.
- the patient starts another drug or herb for ALS during the study.
Key Trial Info
Start Date :
March 16 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 16 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03272802
Start Date
March 16 2017
End Date
September 16 2019
Last Update
March 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
EMG Department, Alzahra Hospital
Isfahan, Iran